Company Overview and News

0
Price list of the world’s costliest tower starts doing the rounds as new owners look for buyers

2018-05-30 scmp
A price list of 48 floors of The Center, the world’s costliest tower bought by a consortium of investors from Hong Kong, is being circulated to gauge market sentiment for a possible resale, hardly a month since the record HK$40.2 billion (US$5.2 billion) deal was completed.
0813 SIOPF SHMAY

0
Sun Hung Kai pays HK$25.1 billion for Hong Kong’s costliest residential land at Kai Tak

2018-05-15 scmp
One of the city’s largest land owners won the 14th government tender by paying a record HK$25.1 billion for a plot with gross floor area of 1.42 million sq ft
SHGKY KRYPY 0086 LFSYF 0083 1212 0683 0012 SUHJF SUHJY 0016 SHGKF 0813 M35 SHMAY SIOPF KRYPF LFSYY

17
How did 10 investors divvy up a 73-storey office tower? They picked ping pong balls from a hat

2018-05-05 scmp
With the ink barely dry on the completion of the world’s most expensive real estate deal, some buyers are already putting their shares of the spoil on the market for a premium
DBSDY MS.PRE 0053 MS.PRF GULRY MS.PRG MS.PRA D05 0813 MS.PRI DBSDF MS.PRK GULRF SHMAY SIOPF MS

12
Here’s how 10 buyers went around their banks and ended up owning the world’s costliest tower

2018-05-02 scmp
A consortium of property investors led by two Hong Kong tycoons yesterday closed their HK$40.2 billion (US$5.15 billion) takeover of Li Ka-shing’s The Center building, in an innovative bit of financial engineering that required them to put up capital equivalent to 20 per cent of their purchase.
0813 MS.PRI MS.PRK SIOPF SHMAY MS.PRE MS.PRF MS.PRG MS MS.PRA

0
Shimao Property Holdings Ltd. 2017 Q4 - Results - Earnings Call Slides

2018-03-28 seekingalpha
The following slide deck was published by Shimao Property Holdings Ltd. in conjunction with their 2017 Q4 earnings call.
0813 SIOPF SHMAY

0
Five Hong Kong-listed Chinese property developers to see big rises in 2017 profit

2018-03-25 scmp
Surging property sales and rising margins will lift profits, though the effect of property market curbs adds a note of uncertainty
SOHOF 0410 0813 SIOPF SHMAY

0
Loan to Acquire Hong Kong's Most Expensive Office Tower Gets Costlier - Bloomberg

2018-03-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
0813 SIOPF SHMAY

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...